COMPOSITIONS AND METHODS COMPRISING KLK3, PSCA, OR FOLH1 ANTIGEN

(19)

(11)

EP 2 155 243 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	18.02.2015 Bulletin 2015/08

(45)	Mention of the grant of the patent:
	03.12.2014 Bulletin 2014/49

(21)	Application number: 08754370.8

(22)	Date of filing: 12.05.2008

(51)

International Patent Classification (IPC):

A61K 39/00^(2006.01)
A61P 35/00^(2006.01)
C07K 19/00^(2006.01)

A61K 39/02^(2006.01)
C07K 14/47^(2006.01)

(86)	International application number:
	PCT/US2008/006048

(87)	International publication number:
	WO 2008/140812 (20.11.2008 Gazette 2008/47)

(54)	COMPOSITIONS AND METHODS COMPRISING KLK3, PSCA, OR FOLH1 ANTIGEN ZUSAMMENSETZUNGEN UND VERFAHREN MIT KLK3; PSCA ODER FOLH1-ANTIGEN COMPOSITIONS ET PROCÉDÉS COMPRENANT DES ANTIGÈNES KLK3, PSCA OU FOLH1

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30)

Priority:

10.05.2007 US 798177

(43)	Date of publication of application:
	24.02.2010 Bulletin 2010/08

(60)	Divisional application:
	14195065.9

(73)	Proprietors:
	The Trustees of the University of Pennsylvania Philadelphia, PA 19104-6283 (US) Advaxis, Inc. Princeton, NJ 08540 (US)

(72)	Inventors:
	PATERSON, Yvonne Philadelphia, PA 19143 (US) ROTHMAN, John Lebanon, NJ 08833 (US) SHAHABI, Vafa Valley Forge, PA 19481 (US)

(74)	Representative: Korn, Richard Mervyn
	Pearl Cohen Zedek Latzer Baratz UK LLP The Gridiron Building One Pancras Square London N1C 4AG London N1C 4AG (GB)

(56)

References cited: :

WO-A2-2005/071088
US-A1- 2003 220 239
US-A1- 2006 104 991
US-A1- 2006 223 835

WO-A2-2006/036550
US-A1- 2004 058 342
US-A1- 2006 210 540

SEWELL D A ET AL: "REGRESSION OF HPV-POSITIVE TUMORS TREATED WITH A NEW LISTERIA MONOCYTOGENES VACCINE", ARCHIVES OF OTOLARYNGOLOGY HEAD AND NECK SURGERY, AMERICAN MEDICAL ASSOCIATION, US, vol. 130, no. 1, 1 January 2004 (2004-01-01), pages 92-97, XP009031081, ISSN: 0886-4470, DOI: DOI:10.1001/ARCHOTOL.130.1.92
SEWELL D A ET AL: "Recombinant Listeria Vaccines Containing PEST Sequences Are Potent Immune Adjuvants for the Tumor-Associated Antigen Human Papillomavirus-16 E7", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 64, no. 24, 15 December 2004 (2004-12-15), pages 8821-8825, XP008119032, ISSN: 0008-5472
FARZANA HUSSAIN S ET AL: "What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 54, no. 6, 1 June 2005 (2005-06-01), pages 577-586, XP019333127, ISSN: 1432-0851, DOI: DOI:10.1007/S00262-004-0600-2
VAFA SHAHABI ET AL: "Development of a Listeria monocytogenes based vaccine against prostate cancer", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 57, no. 9, 14 February 2008 (2008-02-14), pages 1301-1313, XP019624387, ISSN: 1432-0851

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).